LUNG Pulmonx Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUNG

Price (delayed)

$9.67

Market cap

$372.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$330.3M

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment ...

Highlights
The revenue has grown by 28% YoY and by 6% from the previous quarter
Pulmonx's gross profit has increased by 27% YoY and by 7% from the previous quarter
Pulmonx's debt has surged by 70% YoY
The quick ratio is down by 31% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://pulmonx.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of LUNG
Market
Shares outstanding
38.54M
Market cap
$372.66M
Enterprise value
$330.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.13
Price to sales (P/S)
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.81
Earnings
Revenue
$68.68M
EBIT
-$57.04M
EBITDA
-$52.81M
Free cash flow
-$38.42M
Per share
EPS
-$1.6
Free cash flow per share
-$1.01
Book value per share
$3.09
Revenue per share
$1.81
TBVPS
$4.62
Balance sheet
Total assets
$177.78M
Total liabilities
$59.47M
Debt
$41.42M
Equity
$118.32M
Working capital
$127.27M
Liquidity
Debt to equity
0.35
Current ratio
6.5
Quick ratio
5.59
Net debt/EBITDA
0.8
Margins
EBITDA margin
-76.9%
Gross margin
73.9%
Net margin
-88.6%
Operating margin
-90.2%
Efficiency
Return on assets
-32.1%
Return on equity
-46.6%
Return on invested capital
-51.2%
Return on capital employed
-36.9%
Return on sales
-83.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LUNG stock price

How has the Pulmonx stock price performed over time
Intraday
3.09%
1 week
32.83%
1 month
21.64%
1 year
-22.39%
YTD
-24.16%
QTD
4.31%

Financial performance

How have Pulmonx's revenue and profit performed over time
Revenue
$68.68M
Gross profit
$50.75M
Operating income
-$61.94M
Net income
-$60.84M
Gross margin
73.9%
Net margin
-88.6%
The revenue has grown by 28% YoY and by 6% from the previous quarter
Pulmonx's gross profit has increased by 27% YoY and by 7% from the previous quarter
Pulmonx's net margin has increased by 19% YoY and by 6% QoQ
Pulmonx's operating margin has increased by 17% YoY and by 7% from the previous quarter

Growth

What is Pulmonx's growth rate over time

Valuation

What is Pulmonx stock price valuation
P/E
N/A
P/B
3.13
P/S
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.81
The company's equity fell by 23% YoY and by 6% QoQ
The P/B is 13% lower than the last 4 quarters average of 3.5
The revenue has grown by 28% YoY and by 6% from the previous quarter
The price to sales (P/S) is 28% less than the last 4 quarters average of 7.2

Efficiency

How efficient is Pulmonx business performance
The company's return on equity fell by 33% YoY and by 6% QoQ
Pulmonx's ROS has increased by 22% YoY and by 7% from the previous quarter
LUNG's return on invested capital is up by 16% year-on-year and by 4.8% since the previous quarter
The ROA fell by 13% YoY

Dividends

What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUNG.

Financial health

How did Pulmonx financials performed over time
Pulmonx's total assets is 199% more than its total liabilities
Pulmonx's total liabilities has increased by 50% YoY
The quick ratio is down by 31% year-on-year and by 10% since the previous quarter
Pulmonx's debt is 65% lower than its equity
The debt to equity has surged by 119% year-on-year and by 2.9% since the previous quarter
Pulmonx's debt has surged by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.